FDA 483 OBSERVATION · #95 OF 1,923 MOST-CITED
Management review - Lack of or inadequate procedures
FDA cited this observation 303 times across 286 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
Management with executive responsibility did not review the suitability and effectiveness of the quality system at defined intervals with adequate procedures, so leadership oversight of the quality system was missing or inadequate.
Why FDA writes it — Management review is how leadership ensures the quality system actually works and gets the resources it needs. Without it, systemic quality problems have no path to executive attention, and the quality system drifts — which FDA treats as a failure of the system’s governance.
- Establish procedures and conduct management reviews at defined intervals with sufficient frequency.
- Review the suitability and effectiveness of the quality system to ensure it meets requirements and the quality policy and objectives.
- Document that reviews occurred and the decisions and actions taken (the underlying dates and results may be protected from disclosure per the regulation, but their occurrence must be demonstrable).
- Ensure adequate resources are assigned as a result of the review.
- Reviews held informally without procedures, defined intervals, or evidence they occurred.
- Reviews that do not drive resource and improvement decisions, so they change nothing.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.7× the rate of the average FDA-cited firm (13.3% vs 7.8%), across 286 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Procedures for management review have not been adequately established.
Procedures for management review have not been established.
Procedures for management review have not been adequately established.
Procedures for management review have not been established.
Procedures for management review have not been adequately established.
Procedures for management review have not been adequately established.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →